SCHEMBL4084232

SCHEMBL4084232

CC(C)[C@@H](COc1ccc2cc(-c3n[nH]c4ccc(-c5n[nH]c(CC(C)(C)C)n5)cc34)ccc2c1)N1CCCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 2/20 0.47
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37
LRRK2 Q5S007 15/20 0.36
MAPK8 P45983 2/20 0.35
GAK O14976 1/20 0.35
DYRK3 O43781 1/20 0.35
JAK2 O60674 1/20 0.35
PRKD3 O94806 1/20 0.35
MAP4K4 O95819 1/20 0.35
NQO2 P16083 1/20 0.35
CSNK2A2 P19784 1/20 0.35
FECH P22830 1/20 0.35
JAK1 P23458 1/20 0.35
TYK2 P29597 1/20 0.35
MAPK9 P45984 1/20 0.35
CSNK1A1 P48729 1/20 0.35
CSNK1E P49674 1/20 0.35
CLK1 P49759 1/20 0.35
CLK2 P49760 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4171388 1.00 CSNK1D (0.47) CSNK1DCNR1CNR2LRRK2MAPK8
SCHEMBL13812025 0.85 CLK2 (0.39) CSNK1DLRRK2MAPK8GAKDYRK3
SCHEMBL13812061 0.81 CSNK1D (0.40) CSNK1DCNR1CNR2LRRK2MAPK8
SCHEMBL13812272 0.79 TTK (0.39) CSNK1DCNR1CNR2LRRK2MAPK8
SCHEMBL13811898 0.79 CHRNB2 (0.45) CSNK1D
SCHEMBL13812276 0.79 CSNK1D (0.45) CSNK1DMAPK8GAKDYRK3JAK2
SCHEMBL4089419 0.78 CSNK1D (0.43) CSNK1DCNR1CNR2LRRK2MAPK8
SCHEMBL13812166 0.77 CSNK1D (0.43) CSNK1DCNR1CNR2LRRK2MAPK8
SCHEMBL4079733 0.77 CSNK1D (0.43) CSNK1DCNR1CNR2LRRK2MAPK8
SCHEMBL13812054 0.77 CSNK1D (0.43) CSNK1DCNR1CNR2LRRK2MAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2065383-A1 Indazole compounds and methods of use thereof as protein kinase inhibitors Signal Pharmaceuticals, Inc. (US) 2009-06-03 EP disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 US disclosed
US-20060004043-A1 Indazole compounds and methods of use thereof BHAGWAT SHRIPAD S 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF WNT3, WNT3A, WNK3 CSNK1D 702/4885CNR1 2729/4885CNR2 2105/4885
US-20060004043-A1 Indazole compounds and methods of use thereof WNT3, WNT3A, WNK3 CSNK1D 687/4885CNR1 2666/4885CNR2 2016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.